DR. PERRY D. NISEN - Corporate Board Profile

TEVA PHARMACEUTICAL INDUSTRIES LTD

Filing Date	Source Excerpt
2018-04-25	Dr. Perry D. Nisen Independent Director Committees: Science and Technology (Chair) Compliance Dr. Nisen joined the Board of Directors in July 2017. From 2014 to 2017, Dr. Nisen served as Chief Executive Officer and the Donald Bren Chief Executive Chair of Sanford Burnham Prebys Medical Discovery Institute. From 2004 to 2014, Dr. Nisen held various roles at GlaxoSmithKline, most recently as Senior Vice President, Science and Innovation. Prior to that, Dr. Nisen served as Divisional Vice President, Global Oncology Development and as Divisional Vice President, Cancer Research at Abbott Laboratories from 1997 to 2004. Previously, he was the Lowe Foundation Professor of Neuro-Oncology at the University of Texas Southwestern Medical Center. Dr. Nisen has served as a director of Mirna Therapeutics since 2016. He received a B.S. from Stanford University, a Masters degree in molecular biology, and an M.D. and PhD from Albert Einstein College of Medicine. 2017 Director Compensation Dr. Perry D. Nisen 81,712 130,001 211,713
2019-04-16	Dr. Perry D. Nisen Independent Director Committees: Science and Technology (Chair), Compliance. 2018 Director Compensation: Dr. Perry D. Nisen Fees Earned or Paid in Cash ($) 100,000, Stock Awards ($) 130,002, Total 230,002.
2020-04-22	Dr. Perry D. Nisen Independent Director Committees: Science and Technology (Chair) Compliance Dr. Nisen joined the Board of Directors in July 2017. In 2018 he joined Soffinova Investments as Executive Partner, Private Equity. From 2014 to 2017, Dr. Nisen served as Chief Executive Officer and the Donald Bren Chief Executive Chair of Sanford Burnham Prebys Medical Discovery Institute. From 2004 to 2014, Dr. Nisen held various roles at GlaxoSmithKline, most recently as Senior Vice President, Science and Innovation. From 1997 to 2004, Dr. Nisen served as Divisional Vice President, Global Oncology Development, and as Divisional Vice President, Cancer Research, at Abbott Laboratories. Previously, he was the Lowe Foundation Professor of Neuro-Oncology at the University of Texas Southwestern Medical Center. Dr. Nisen has served as a director of Mirna Therapeutics since 2016. He received a B.S. from Stanford University, a Masters degree in molecular biology, and an M.D. and PhD from Albert Einstein College of Medicine. With extensive experience in medical research and development and management positions in leading pharmaceutical companies, Dr. Nisen provides a unique perspective on business and R&D activities.
2021-04-21	Dr. Perry D. Nisen Independent Director Committees: Science and Technology (Chair), Compliance Dr. Nisen joined the Board of Directors in 2017. In 2018 he joined Soffinova Investments as Executive Partner, Private Equity. From 2014 to 2017, Dr. Nisen served as Chief Executive Officer and the Donald Bren Chief Executive Chair of Sanford Burnham Prebys Medical Discovery Institute. From 2004 to 2014, Dr. Nisen held various roles at GlaxoSmithKline, most recently as Senior Vice President, Science and Innovation. From 1997 to 2004, Dr. Nisen served as Divisional Vice President, Global Oncology Development, and as Divisional Vice President, Cancer Research, at Abbott Laboratories. Previously, he was the Lowe Foundation Professor of Neuro-Oncology at the University of Texas Southwestern Medical Center. Dr. Nisen has served as a director of Mirna Therapeutics since 2016. He received a B.S. from Stanford University, a Masters degree in molecular biology, and an M.D. and PhD from Albert Einstein College of Medicine. 2020 Director Compensation: Dr. Perry D. Nisen Fees Earned or Paid in Cash ($) 160,000 Stock Awards ($) 159,997 Total ($) 319,997
2022-04-13	Dr. Perry D. Nisen Independent Director Committees: Science and Technology (Chair) Compliance Dr. Nisen joined the Board of Directors in 2017. In July 2021, he became Chief Executive Officer of Quanta Therapeutics Inc., a privately held biotechnology company. In 2018, he joined Soffinova Investments as Executive Partner, Private Equity and transitioned in January 2021 to a consultant role. From 2014 to 2017, Dr. Nisen served as Chief Executive Officer and the Donald Bren Chief Executive Chair of Sanford Burnham Prebys Medical Discovery Institute. From 2004 to 2014, Dr. Nisen held various roles at GlaxoSmithKline, most recently as Senior Vice President, Science and Innovation. From 1997 to 2004, Dr. Nisen served as Divisional Vice President, Global Oncology Development, and as Divisional Vice President, Cancer Research, at Abbott Laboratories. Previously, he was the Lowe Foundation Professor of Neuro-Oncology at the University of Texas Southwestern Medical Center. From 2016 to 2017, Dr. Nisen served as a director of Mirna Therapeutics, Inc. He received a B.S. from Stanford University, a Masters degree in molecular biology, and an M.D. and PhD from Albert Einstein College of Medicine.
2023-04-19	Dr. Perry D. Nisen joined the Board of Directors in 2017. ... Committees: Science and Technology (Chair), Compliance. ... 2022 Director Compensation: Fees Earned or Paid in Cash $160,000, Stock Awards $159,997, Total $319,997.
2024-04-16	Dr. Perry D. Nisen Independent Director Committees: Science and Technology (Chair), Compliance, Human Resources and Compensation ... Dr. Nisen joined the Board of Directors in 2017. ... 2023 Director Compensation table shows Dr. Perry D. Nisen total compensation as $327,869.